Meeting
2017 ASCO Annual Meeting
Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma.
Authors
Louise Sayers
Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
Louise Sayers , Jeremy Howard Lewin , Damien Kee , Imogen Walpole , Alexandra Sanelli , Alan Herschtal , John Spillane , David E. Gyorki , David Speakman , Vanessa Estall , Simon Donahoe , Miklos Pohl , Kathy Pope , Margaret Chua , Shahneen Kaur Sandhu , Grant A. McArthur , Christopher McCormack , Michael A. Henderson , Rodney J Hicks , Mark J. Shackleton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9563)
DOI
10.1200/JCO.2017.35.15_suppl.9563
Abstract #
9563
Poster Bd #
171
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A single-center comparative surveillance strategies of ctDNA (Signatera), imaging, and CEA in the surveillance of resected colorectal cancer.
First Author: Jaideep Singh Sandhu
Poster
2023 ASCO Annual Meeting
Tumor-informed circulating tumor DNA (TI-ctDNA) based molecular residual disease (MRD) detection and relapse risk for patients with stage II-IV melanoma in surgical remission: A single center experience.
First Author: Logan Rhea
Poster
2023 ASCO Annual Meeting
Risk of further progression or death among durable progression-free survivors with melanoma in PD-1 blockade trials: Implications for imaging surveillance.
First Author: Lei Deng
Poster
2022 ASCO Annual Meeting
The interferon-gamma (IFN-y) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma.
First Author: Irene L.M. Reijers